Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial — Shinichi Ohkawa (2015) | RDL Network
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial
Andrew X. Zhu, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weißinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek‐Yeol Ryoo, Y. Choi, Hyun Cheol Chung, Chung‐Pin Li, Chia‐Jui Yen, Kuan‐Der Lee, Ling Yang, Ian Chau
Andrew X. Zhu, Baek‐Yeol Ryoo, Chung‐Jen Yen, Masatoshi Kudo, Ronnie T. P. Poon, Davide Pastorelli, J.-F. Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shan‐Chwen Chang, Paolo Abada, Lifen Yang, Jonathan D. Schwartz, Joon Oh Park
Andrew X. Zhu, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weißinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek‐Yeol Ryoo, Y. Choi, Hyun Cheol Chung, Chung‐Pin Li, Chia-Jui Yen, Kuan‐Der Lee, Shao-Chun Chang, Ling Yang, Paolo Abada, Ian Chau
J.-F. Blanc, Stephen L. Chan, J.O. Park, Baek‐Yeol Ryoo, Chung‐Jen Yen, Masatoshi Kudo, Rtp Poon, Davide Pastorelli, Ari David Baron, Tatiana Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Paolo Abada, Samuel Chang, Ling Yang, Alice Zhu
Discussion(0)
No comments yet. Be the first to comment.